217799-03-6
217799-03-6 结构式
基本信息
Benzoic acid, 2-[[[4-[[(4-chlorophenyl)sulfonyl]amino]butyl][[3-[[4-(1-methylethyl)-2-thiazolyl]methoxy]phenyl]methyl]amino]sulfonyl]-
物理化学性质
| 报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
| 2025/05/22 | HY-U00253 | KP496 | 217799-03-6 | 1 mg | 3000元 |
| 2025/05/22 | HY-U00253 | KP496 | 217799-03-6 | 10 mM * 1 mLin DMSO | 10356元 |
| 2024/08/19 | HY-U00253 | 217799-03-6 KP496 | 217799-03-6 | 5mg | 8500元 |
常见问题列表
|
LTD 4
|
TXA 2 Receptor
|
KP496 significantly inhibits acute (day 7) and chronic (day 21) lung inflammation. KP496 attenuates the number of lymphocytes on day 7 and those of macrophages, neutrophils, and eosinophils on days 7 and 21. KP496 and prednisolone significantly suppress the increase of hydroxyl-L-proline content in the lung. Compare to respective vehicle control group, the inhibition ratio of KP496 and prednisolone for increase of hydroxyl-L-proline content is about 74 and 63%, respectively. The KP496 (100 mg/head) group and prednisolone (10 mg/kg) group exhibit significant inhibition of numbers of infiltrating total cells, eosinophils, monocytes/macrophages, and lymphocytes compare with the control group. Infiltration of all types of cells except neutrophils is decreased in the KP496 (30m g/head) group, though not to significant extents.